Main > ONCOLOGY (**) > Breast Cancer>HER2+>Adjuvant *** > USA. G. PertuzuMAb+TrastuzuMAb+ IV

---

USA. G. PertuzuMAb+TrastuzuMAb+ IV's subsections
(*) USA Approval Date: 2017. 12.20.
+DoceTaxel
Company
Duration: 150 Minutes
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 5
Patent>UpDate: 2017. 12.19
TradeMark
TradeMark Web-Site

USA. G. PertuzuMAb+TrastuzuMAb+ IV's products
This section has no products